Literature DB >> 20160495

ZD6474 coerces breast cancer for an apoptotic journey.

Binoj C Nair1, Ratna K Vadlamudi.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20160495      PMCID： PMC3010236          DOI： 10.4161/cbt.9.8.11318

Source DB:  PubMed          Journal:  Cancer Biol Ther        ISSN： 1538-4047            Impact factor:   4.742


× No keyword cloud information.
  17 in total

Review 1.  Overview of tyrosine kinase inhibitors in clinical breast cancer.

Authors:  A Agrawal; E Gutteridge; J M W Gee; R I Nicholson; J F R Robertson
Journal:  Endocr Relat Cancer       Date:  2005-07       Impact factor: 5.678

Review 2.  ErbB receptors: from oncogenes to targeted cancer therapies.

Authors:  Hongtao Zhang; Alan Berezov; Qiang Wang; Geng Zhang; Jeffrey Drebin; Ramachandran Murali; Mark I Greene
Journal:  J Clin Invest       Date:  2007-08       Impact factor: 14.808

3.  Panitumumab.

Authors:  Leonard Saltz; Chris Easley; Peter Kirkpatrick
Journal:  Nat Rev Drug Discov       Date:  2006-12       Impact factor: 84.694

Review 4.  EGFR antagonists in cancer treatment.

Authors:  Fortunato Ciardiello; Giampaolo Tortora
Journal:  N Engl J Med       Date:  2008-03-13       Impact factor: 91.245

Review 5.  Epidermal growth factor receptors: critical mediators of multiple receptor pathways.

Authors:  P O Hackel; E Zwick; N Prenzel; A Ullrich
Journal:  Curr Opin Cell Biol       Date:  1999-04       Impact factor: 8.382

6.  Epidermal growth factor receptor expression in breast cancer association with biologic phenotype and clinical outcomes.

Authors:  Mothaffar F Rimawi; Priya B Shetty; Heidi L Weiss; Rachel Schiff; C Kent Osborne; Gary C Chamness; Richard M Elledge
Journal:  Cancer       Date:  2010-03-01       Impact factor: 6.860

7.  Vascular permeability factor (vascular endothelial growth factor) expression and angiogenesis in patients with ductal carcinoma in situ of the breast.

Authors:  A J Guidi; S J Schnitt; L Fischer; K Tognazzi; J R Harris; H F Dvorak; L F Brown
Journal:  Cancer       Date:  1997-11-15       Impact factor: 6.860

Review 8.  Role of vascular endothelial growth factor during breast cancer.

Authors:  N E Kushlinskii; E S Gershtein
Journal:  Bull Exp Biol Med       Date:  2002-06       Impact factor: 0.804

Review 9.  Combined targeting of EGFR-dependent and VEGF-dependent pathways: rationale, preclinical studies and clinical applications.

Authors:  Giampaolo Tortora; Fortunato Ciardiello; Giampietro Gasparini
Journal:  Nat Clin Pract Oncol       Date:  2008-07-01

Review 10.  Bevacizumab in metastatic breast cancer: a meta-analysis of randomized controlled trials.

Authors:  A Valachis; N P Polyzos; N Alpha Patsopoulos; V Georgoulias; D Mavroudis; D Mauri
Journal:  Breast Cancer Res Treat       Date:  2010-01-09       Impact factor: 4.872
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.